ArticleBMC cancer2026
Sex differences in gastric cancer mutational burden reflect MLH1-associated epigenetic regulation.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor mutational burden (TMB) is widely used as a biomarker for predicting response to immune checkpoint inhibitors. Therefore, understanding its variability across patient groups, particularly between sexes, and its underlying biological determinants is of critical importance.
methodsWe analyzed autosomal TMB and its association with DNA repair-related regulatory mechanisms in gastric cancer across TCGA-STAD and independent targeted sequencing cohorts. Sex-stratified analyses were integrated with gene expression, promoter methylation, and regression modeling.
resultsFemale tumors exhibited significantly higher autosomal TMB compared with male tumors, with differences most pronounced in older female patients. Across tumors, TMB was strongly associated with reduced MLH1 expression and increased MLH1 promoter methylation, while female tumors exhibited significantly higher MLH1 methylation levels. These relationships are consistent with mismatch repair deficiency as a major driver of mutation accumulation. In multivariable regression models adjusting for MLH1 methylation and expression, the association between sex and TMB was attenuated, suggesting that MLH1-related processes contribute to the observed sex differences. Subtype-aware analyses further suggested that the female-associated TMB elevation was partly related to increased representation of MSI/MMR-deficient tumors among females, while female and male MSI tumors showed comparable TMB. Independent targeted sequencing cohorts showed consistent directional trends, although these did not reach statistical significance.
conclusionsTogether, our findings indicate that sex differences in mutation burden are linked to MLH1-associated epigenetic regulation, mismatch repair deficiency, and MSI/MMR-deficient tumor biology. These results highlight the importance of incorporating sex-specific molecular context into the interpretation of genomic biomarkers and support a more refined, biologically informed approach to precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.